For education only · Not medical advice
← All articles
September 2026 Weight & Metabolic 6 min read

Tirzepatide side effects, as recorded in the trials

Tirzepatide is one of the few peptides on this site with a real safety dataset behind it, which means the honest answer about its side effects comes from trial tables and a current prescribing label rather than from forum reports, so this page works through what those documents actually record.

The short answer

  • The common tirzepatide side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, abdominal pain and dyspepsia, each reported in at least 5% of people on the label. They cluster during dose escalation.
  • Also at least 5%: injection-site reactions, fatigue, hypersensitivity reactions, eructation (burping), hair loss and reflux.
  • The serious warnings are a separate and shorter list, headed by a boxed warning for thyroid C-cell tumours, which comes from rats.
  • Two things changed in 2026. The suicidal behaviour and ideation warning was removed from the US label in February 2026 after an FDA class review. The Canadian monograph added an eye-nerve precaution in June 2026 that the US label does not carry.
  • Anti-drug antibodies are far more common than people expect: 51% of adults in the Mounjaro label’s immunogenicity data over 40 to 104 weeks.

What the trials recorded, and where it clustered

Tirzepatide’s evidence base is large. SURPASS covered type 2 diabetes and SURMOUNT covered weight, with the longest follow-up running to 176 weeks. Across that programme the tolerability signature is consistent and unglamorous: the gut complains, mostly while the dose is going up.

The label lists nausea, diarrhoea, vomiting, constipation, abdominal pain and dyspepsia as events occurring in at least 5% of treated patients, and notes they are mostly associated with the escalation phase. That is the practical shape of the problem. Trial dose escalation ran in 2.5 mg steps every 4 weeks, and the label’s initiation dose of 2.5 mg weekly for 4 weeks exists to get people through that window rather than to do anything therapeutic.

Injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastro-oesophageal reflux round out the at-least-5% list. None of these is trivial to the person experiencing it, but none is the reason the drug carries a boxed warning.

Half-life matters for interpreting all of this. Tirzepatide’s half-life is about 5 days, stated as 5 to 6 days in overweight and obesity in the Zepbound label, with steady state reached after 4 weeks. A side effect that starts on a Tuesday does not end on a Wednesday.

The label warnings

As of the US label dated August 2026, the warnings are:

  • Thyroid C-cell tumours (boxed). This comes from rodent studies. GLP-1 receptor agonists activate rat thyroid C-cells, which express far more GLP-1 receptor than human C-cells do. The human epidemiology conflicts: a French nested case-control study reported higher thyroid cancer risk after 1 to 3 years of GLP-1 agonist use, while a large Scandinavian active-comparator cohort found no substantial increase. Detection bias, meaning more neck imaging in treated patients, may contribute. The contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2 stands regardless.
  • Severe gastrointestinal reactions. Not recommended in severe gastroparesis.
  • Acute kidney injury from volume depletion, usually on the back of vomiting or diarrhoea.
  • Acute gallbladder disease and acute pancreatitis.
  • Serious hypersensitivity.
  • Hypoglycaemia when combined with insulin or a sulfonylurea. Tirzepatide’s glucose effects are glucose-dependent, so it rarely causes hypoglycaemia alone; the labels advise reducing the insulin or sulfonylurea dose at initiation.
  • Diabetic retinopathy complications in type 2 diabetes, linked to rapid glucose lowering in people who already have retinopathy.
  • Pulmonary aspiration during general anaesthesia or deep sedation.

Contraindications: personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity. It is not for type 1 diabetes.

Routine calcitonin measurement or thyroid ultrasound is described in the labels themselves as of uncertain value, which is worth knowing before paying for either.

The two 2026 changes

The suicidality warning came off. FDA issued a drug safety communication on 13 January 2026 requesting removal of the suicidal behaviour and ideation warning from this drug class after a class review found no increased risk. The removal was confirmed in February 2026 label supplements. If you are reading older coverage, it is out of date on this point.

Canada added an eye precaution the US did not. The Canadian Zepbound monograph of June 2026 added a GLP-1 class precaution for non-arteritic anterior ischaemic optic neuropathy, or NAION: urgent ophthalmology referral for sudden vision loss, and stop the drug if NAION is confirmed. That precaution is not in the US label as of September 2026. The NAION signal came out of observational work on semaglutide, and in June 2025 the European regulator’s safety committee concluded NAION is a very rare side effect of semaglutide, at up to 1 in 10,000.

Two effects that get argued about

Anti-drug antibodies. The Mounjaro label reports antibodies to tirzepatide in 51% of adults over 40 to 104 weeks of treatment. Of those who were antibody-positive, 34% cross-reacted with native GIP and 14% with native GLP-1, and about 2% developed antibodies that neutralised tirzepatide’s activity at each receptor. Hypersensitivity reactions ran 4.1% in antibody-positive patients versus 3.0% in antibody-negative ones. For comparison, the semaglutide figure on the Wegovy label is 3% over 68 weeks. The labels are explicit that antibody rates depend on assay sensitivity and cannot be compared across products, so the lesson is not that one drug is “more immunogenic”. The lesson is that even a well-made, approved peptide raises antibodies in a meaningful share of users, sometimes antibodies that recognise the body’s own hormones.

Lean mass. In the SURMOUNT-1 DXA substudy, about 25% of the weight lost was lean mass, the same proportion as with placebo-associated weight loss. That number is often quoted as if it were unique to the drug. It is not. It is what weight loss does, which is why protein intake and resistance training belong in any plan alongside pharmacotherapy.

Interactions and timing worth planning for

Oral contraceptives. Both the US and Canadian labels instruct switching from an oral hormonal contraceptive to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Delayed gastric emptying reduces oral contraceptive exposure. Semaglutide labels do not carry this instruction; tirzepatide’s does.

Other oral drugs. Narrow-therapeutic-index drugs such as warfarin deserve monitoring for the same reason.

Procedures. The 2024 multisociety perioperative guidance advises that most patients can continue GLP-1 receptor agonists, but those at higher risk of delayed gastric emptying, meaning the escalation phase, higher doses, weekly dosing or active gastrointestinal symptoms, should follow a liquid diet for 24 hours before the procedure or use other individualised measures. Tell the anaesthesia team about any GLP-1-active product.

Lipase. Asymptomatic rises in pancreatic enzymes are common with this class. In pooled liraglutide data, lipase above the upper limit of normal occurred in 43.5% on liraglutide 3.0 mg versus 15.1% on placebo, with very low predictive value for pancreatitis. The sensible conclusion is to test when symptoms suggest pancreatitis, not routinely.

A word on what is not the approved product

FDA declared the tirzepatide shortage resolved on 19 December 2024, and enforcement discretion for compounded copies ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities. By 31 May 2026 FDA had received more than 730 adverse-event reports for compounded tirzepatide. Health Canada’s advisory RA-81518 of 21 January 2026 names Mounjaro and Zepbound as the only authorised tirzepatide products in Canada, and tirzepatide appeared among unauthorised injectable peptides seized from an online seller in an August 2025 advisory.

None of the safety data above describes a vial of unknown origin. Trial safety tables belong to the molecule that was tested, made the way it was made. A label that says “research use only” carries no legal status of its own, and Health Canada said so directly in its 9 April 2026 advisory.

For the wider picture on this molecule, see the tirzepatide profile, the three-way comparison with semaglutide and retatrutide, and the GLP-1 overview.

The bottom line

Tirzepatide’s common side effects are gastrointestinal and front-loaded into the escalation weeks, and its half-life of about 5 days means they resolve slowly. The serious list is short, headed by a rodent-derived boxed warning and a real contraindication for medullary thyroid carcinoma and MEN 2, plus planning points for oral contraceptives, anaesthesia and insulin co-therapy. Two 2026 changes matter: the suicidality warning is gone in the US, and Canada added a NAION precaution the US label does not have.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Peptides 101TirzepatideSafety
For education only · Not medical advice